Insulet | PODD - Current Liabilities


Insulet reported $744.2M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Align Technology USD 1.91B 2.74M Jun/2026
AtriCure USD 81.92M 8.72M Jun/2026
Baxter International USD 3.59B 102M Jun/2026
Becton, Dickinson and Co. USD 9.4B 897M Jun/2026
Boston Scientific USD 6.43B 1.86B Jun/2026
Cardinal Health USD 43.9B 1.92B Jun/2026
Cooper Companies USD 1.8B 209M Mar/2026
Dexcom USD 2.36B 133.9M Jun/2026
Edwards Lifesciences USD 1.51B 98.9M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Globus Medical USD 479.35M 3.12M Jun/2026
ICU Medical USD 498.36M 19.54M Jun/2026
Inogen USD 64.94M 2.12M Sep/2025
Insulet USD 744.2M 56.7M Jun/2026
Integra LifeSciences USD 330.88M 15.96M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Medtronic USD 9.5B 440M Dec/2025
Merit Medical Systems USD 264.93M 48.06M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Solventum Corp USD 3.66B 317M Jun/2026
Stryker USD 6.68B 369M Jun/2026
Tandem Diabetes Care USD 253M 5.05M Jun/2026
Teleflex USD 720.38M 7.67M Jun/2026
West Pharmaceutical Services USD 640.5M 33.5M Jun/2026
Zimmer Biomet Holdings USD 3.01B 149.2M Jun/2026